Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment

Cancer Lett. 2016 Sep 28;380(1):216-26. doi: 10.1016/j.canlet.2015.07.028. Epub 2015 Jul 31.

Abstract

Angiogenesis is sustained by classical and non-classical proangiogenic factors (PFs) acting in tumor microenvironment and these factors are also potential targets of antiangiogenic therapies. All PFs induce the overexpression of several signaling pathways that lead to migration and proliferation of endothelial cells contributing to tumor angiogenesis and survival of cancer cells. In this review, we have analyzed each PF with its specific receptor/s and we have summarized the available antiangiogenic drugs (e.g. monoclonal antibodies) targeting these PFs, some of these agents have already been approved, others are currently in development for the treatment of several human malignancies.

Keywords: Cancer; Endothelial cells; Novel antiangiogenic therapies; Proangiogenic factors; Tumor angiogenesis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Angiogenic Proteins / antagonists & inhibitors*
  • Angiogenic Proteins / metabolism
  • Animals
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Endothelial Cells / pathology
  • Humans
  • Molecular Targeted Therapy
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Neovascularization, Pathologic*
  • Signal Transduction / drug effects
  • Tumor Microenvironment*

Substances

  • Angiogenesis Inhibitors
  • Angiogenic Proteins